Sign up to save your podcasts
Or
Share Real-World Rx 💊, Real Results 📉: GLP-1 Agents Slash HFpEF Risk
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Real-World Rx 💊, Real Results 📉: GLP-1 Agents Slash HFpEF Risk
💥 Practice-Changing Evidence in HFpEF! 💥
In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉
⚖️ No meaningful difference between the two agents.
🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies' expanding role in cardiometabolic HFpEF 🫀
#Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure
View all episodes
By Dr RR Baliga, MD, MBA
5
66 ratings
💥 Practice-Changing Evidence in HFpEF! 💥
In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉
⚖️ No meaningful difference between the two agents.
🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies' expanding role in cardiometabolic HFpEF 🫀
#Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure
More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast
View all
This Week in Cardiology
907 Listeners
The Curbsiders Internal Medicine Podcast
3,377 Listeners
The Mel Robbins Podcast
20,663 Listeners